Skip to main content
Clinical Trials/NCT04629391
NCT04629391
Recruiting
Not Applicable

Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis. a Randomized Prospective Study

La Tour Hospital1 site in 1 country296 target enrollmentSeptember 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arthritis Shoulder
Sponsor
La Tour Hospital
Enrollment
296
Locations
1
Primary Endpoint
Change in American Shoulder and Elbow Surgeons score (ASES)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.

Detailed Description

Total anatomic shoulder arthroplasty (TSA) is an effective treatment of severe glenohumeral osteoarthritis, with significant improvement in shoulder pain and function. Concerns about glenoid loosening, associated with difficult revision procedures and disappointing outcomes, have however been raised. Reverse total shoulder arthroplasty (RTSA) was designed with a medialized center of rotation to treat cuff tear arthropathy. Favorable early reports led to the expansion of primary indications of RTSA to proximal humeral fractures as well as osteoarthritis with poor glenoid bone stock. Recent reports revealed excellent clinical results of RTSA for primary glenohumeral arthropathy with intact rotator cuff and a low rate of complications. Retrospective studies comparing functional results - of anatomic TSA for treating glenohumeral osteoarthritis with RTSA for rotator cuff arthropathy - found equivalent or greater improvements in American Shoulder and Elbow Surgeons score (ASES) at \>2-year follow-up. In a study comparing anatomic TSA to RTSA for the treatment of glenohumeral osteoarthritis with intact rotator cuffs, Steen et al. reported equivalent functional results at \>2-year follow-up. The retrospective matched cohort study could, however, not eliminate biases, such that RTSA patients had higher preoperative glenoid retroversion than anatomic TSA patients. The authors therefore hypothesize that, in patients treated for glenohumeral osteoarthritis without excessive glenoid retroversion, RTSA will render better functional outcomes than anatomic TSA, at 2 postoperative years. Many other studies confirmed in 2019 Steen's hypothesis. Moreover, several studies revealed good long-term survivorship after RTSA. There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.The secondary goals are 1) to evaluate whether RTSA eventually grants superior postoperative clinical and radiographic outcomes than anatomic TSA (superiority), 2) to determine whether RTSA is associated with fewer postoperative complications than anatomic TSA.

Registry
clinicaltrials.gov
Start Date
September 1, 2020
End Date
October 1, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
La Tour Hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr. Alexandre Lädermann

Principal Investigator

La Tour Hospital

Eligibility Criteria

Inclusion Criteria

  • Primary glenohumeral arthritis,
  • Intact rotator cuff,
  • No important glenoid bone loss (cf exclusion criteria),
  • Patients between 65 and 85 years old
  • Informed Consent as documented by signature (Appendix Informed Consent Form).

Exclusion Criteria

  • B2 glenoid with \> 80% posterior humeral head subluxation or greater 25 degrees neoglenoid retroversion,
  • B3 and C type glenoids,
  • Full thickness rotator cuff tear,
  • Acute or malunited proximal humeral fracture,
  • Chronic locked dislocation
  • Rheumatoid arthritis,
  • Revision surgery or surgical antecedents,
  • Axillary nerve damage,
  • Non-functioning deltoid muscle,
  • Glenoid vault deficiency precluding baseplate fixation,

Outcomes

Primary Outcomes

Change in American Shoulder and Elbow Surgeons score (ASES)

Time Frame: Between baseline and 2 postoperative years

General clinical score (0-100, with 100 being the best score possible)

Secondary Outcomes

  • Change in Constant score(Between baseline and 2 postoperative years)
  • Change in Subjective Shoulder Value (SSV)(Between baseline and 2 postoperative years)
  • Change in Short Form -12 (SF-12)(Between baseline and 2 postoperative years)
  • Radiographic outcomes(2 postoperative years)
  • Change in Range of motion in degrees(Between baseline and 2 postoperative years)
  • Complication rates(2 postoperative years.)
  • Change in pain on visual analogic scale (pVAS)(Between baseline and 2 postoperative years)

Study Sites (1)

Loading locations...

Similar Trials